Rosacea has variable clinical presentation consisting of four overlapping phenotypes: erythematotelangiectatic, papulopustular, phymatous, and ocular.1 Rosacea's pathogenesis involves increased cutaneous density of Demodex folliculorum mites, which drive inflammation through activation of Toll-like receptor-2.1,2 Thus, topical ivermectin (IVM) 1.0% cream's anti-inflammatory and acaricidal activity provides an effective and targeted treatment for moderate-to-severe rosacea. However, literature assessing IVM is limited to efficacy in treating the papulopustular presentation, limiting generalizability.1,3,4 Although our primary endpoint was to assess patient adherence, the objective of this secondary analysis was to assess IVM efficacy in rosacea, regardless of clinical presentation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
β-Triketones from Leptospermum scoparium (mānuka) oil show potential as scabicides.
Phytomedicine
December 2024
Scabies Laboratory, Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; School of Biomedical Sciences, University of Queensland, St Lucia, Brisbane, QLD, Australia. Electronic address:
Background: Scabies is a debilitating and neglected infectious disease with limited effective treatment options and affecting millions of people worldwide, mainly in poor and overcrowded settings. Essential oils from Australasian Myrtaceae are known to have parasiticidal properties, often attributed to the presence of β-triketones, which are known inhibitors of the tyrosine catabolism pathway through inhibition of hydroxyphenylpyruvate dioxygenase (HPPD).
Purpose: In this study, essential oils from mānuka (Leptospermum scoparium) were evaluated in vitro for miticidal and ovicidal activities and their active β-triketone constituents (flavesone, leptospermone, and isoleptospermone) were identified.
Topical Ivermectin-metronidazole gel therapy improves Meibomian gland Function in blepharitis caused by demodex spp.
Cont Lens Anterior Eye
December 2024
Department of Ophthalmology, Molecular Pharmacology and Physiology, FL, United States; Pathology and Cell Biology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States.
Purpose: To evaluate the efficacy and safety of topical Ivermectin- Metronidazol in the management of demodex infestation and their effect in Meibomian gland dysfunction (MGD) METHODS: Fifty-four patients (108 eyes) with demodex diagnosis and Meibomian gland dysfunction received Ivermectin 0.3 %+Metronidazole 0.5 % gel in the night for 5 weeks.
View Article and Find Full Text PDFCase report: Successful treatment of chorioptic mange in two Belgian draft horse foals with topical ivermectin.
Front Vet Sci
November 2024
Laboratory of Veterinary Pathology, Department of Pathobiology, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Introduction: Various draft horse breeds, especially breeds with abundant feathering on the lower limbs, are known to be susceptible to chorioptic mange. Clinical signs of chorioptic mange encompass intense pruritus leading to self-mutilation and hair loss, thickening of the epidermis, and the formation of hyperkeratotic crusts and scabs. Despite the frequent occurrence and high impact of this condition, treatment options are limited, with a conspicuous absence of registered products formulated for equines, and especially foals.
View Article and Find Full Text PDFIvermectin 1% Combined With Intense Pulsed Light Treatment for Dry Eye Disease Secondary to Demodex Blepharitis.
Cornea
December 2024
Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Purpose: To examine the safety and efficacy of combined treatment with topical ivermectin 1% and intense pulsed light (IPL) for dry eye disease (DED) secondary to demodex blepharitis.
Methods: A retrospective review of medical files of patients treated at a private clinic specializing in DED between November 2022 and February 2024 was performed. Sixty-one patients aged 18 years or older with DED because of demodex blepharitis, who received the IPL and ivermectin 1% combination therapy, were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!